Pheniramine
Naphcon-a, Opcon-a, Visine (pheniramine) is a small molecule pharmaceutical. Pheniramine was first approved as Naphcon-a on 1994-06-08. It is used to treat allergic rhinitis perennial, pruritus, and urticaria in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Naphcon-a, Opcon-a, Visine (generic drugs available since 2010-09-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alahist dm | OTC monograph final | 2023-06-08 |
| opcon-a | New Drug Application | 2020-03-11 |
| visine dry eye relief | OTC monograph final | 2023-01-06 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| pruritus | HP_0000989 | D011537 | L29 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AA: Antihistamines for topical use
— D04AA16: Pheniramine
R: Respiratory system drugs
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AB: Substituted alkylamines, systemic antihistamines
— R06AB05: Pheniramine
HCPCS
Code | Description |
|---|---|
| J0945 | Injection, brompheniramine maleate, per 10 mg |
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | 1 | — | — | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | 1 | — | — | 1 |
| Hypertensive intracranial hemorrhage | D020299 | — | — | 1 | — | — | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | 1 | — | — | 1 |
| Subdural hematoma | D006408 | HP_0100309 | — | — | 1 | — | — | 1 | |
| Cerebral intraventricular hemorrhage | D000074042 | — | — | 1 | — | — | 1 | ||
| Atrial flutter | D001282 | EFO_0003911 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENIRAMINE |
| INN | pheniramine |
| Description | N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine is a tertiary amino compound and a member of pyridines. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC(c1ccccc1)c1ccccn1 |
Identifiers
| PDB | — |
| CAS-ID | 86-21-5 |
| RxCUI | 8132 |
| ChEMBL ID | CHEMBL1193 |
| ChEBI ID | — |
| PubChem CID | 4761 |
| DrugBank | DB01620 |
| UNII ID | 134FM9ZZ6M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 677 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more